Plaintiff
4 cases as plaintiff.
Astellas US LLC is the U.S. subsidiary of Astellas Pharma Inc., a Japanese multinational pharmaceutical company headquartered in Tokyo. Astellas Pharma Inc. was formed in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. The parent company is publicly traded on the Tokyo Stock Exchange (TYO: 4503). For the fiscal year ending in March 2026, Astellas Pharma reported revenues of $14.2 billion and has approximately 14,484 employees worldwide. The U.S. headquarters are located in Northbrook, Illinois.
Astellas is an operating pharmaceutical company that discovers, develops, and commercializes prescription drugs. The company's primary therapeutic areas include oncology, urology, immunology (transplantation), ophthalmology, and women's health. Its major products include XTANDI (for prostate cancer), PADCEV (for urothelial cancer), VEOZAH (for symptoms of menopause), Myrbetriq (for overactive bladder), and Prograf (an immunosuppressant to prevent organ rejection). The company operates research and development centers and manufacturing facilities globally, including in the U.S. and Europe.
Based on the provided data, Astellas is an operating company actively enforcing its patent rights. In all four tracked cases, Astellas US LLC or its parent company, Astellas Pharma Inc., is the plaintiff. This litigation history, showing zero instances of the company as a defendant, is characteristic of a research-based pharmaceutical company protecting its products from generic competition. The defendants in these cases—Dr. Reddy's Laboratories, Hikma Pharmaceuticals, Haimen Pharma, and Zydus Pharmaceuticals—are all pharmaceutical companies known for producing generic drugs. The cases are filed in the U.S. District Court for the District of New Jersey, a common venue for pharmaceutical patent litigation.
Watchlist
Email-only, free, anonymous. We'll notify you when Astellas US LLC files another patent-infringement lawsuit. One-click unsubscribe from any alert.
The accused products are generic versions of Xtandi 40 mg and 80 mg tablets.
The claims and counterclaims in this case were dismissed with prejudice, with each party bearing its own costs.
This case has been consolidated with case 3:24-cv-09748 for all purposes. An amended complaint including the '628 patent was filed on January 3, 2025, and the case appears to be ongoing.
This case has been consolidated with case 3:24-cv-09403 and appears to be ongoing. An amended complaint including US patent 12161628 was filed on January 3, 2025.